{"id":173,"date":"2026-05-31T12:44:34","date_gmt":"2026-05-31T12:44:34","guid":{"rendered":"https:\/\/officemovingamerica.com\/?p=173"},"modified":"2026-05-31T12:44:34","modified_gmt":"2026-05-31T12:44:34","slug":"experimental-novartis-radiopharma-drug-shows-promise-in-early-study","status":"publish","type":"post","link":"https:\/\/officemovingamerica.com\/?p=173","title":{"rendered":"Experimental Novartis Radiopharma Drug Shows Promise in Early Study"},"content":{"rendered":"<div>\n<div>\n<p>By Bhanvi Satija<\/p>\n<\/div>\n<div>\n<p>May 31 (Reuters) &#8211; Novartis said on Sunday that \u2060early \u2060data from its experimental actinium-based \u2060drug showed signs of anti-tumour activity against prostate cancer, including in patients \u200bpreviously treated with its older drug Pluvicto.<\/p>\n<p>Read more <a href=\"https:\/\/officemovingamerica.com\/?p=171\">Blue Origin Faces Months of Delays After Rocket Explosion Damages Launch Pad<\/a><\/p>\n<\/div>\n<div>\n<div><\/div>\n<\/div>\n<div>\n<p>Data from a 101-patient study showed that 52.5% of those previously treated \u200cwith Pluvicto saw levels of prostate-specific \u200cantigen, or PSA, fall by at least half when treated with the actinium-based drug. Elevated PSA \u2060level is \u2060a common marker for prostate cancer.<\/p>\n<\/div>\n<div>\n<p>Response rates were higher in prostate cancer \u200bpatients who had not received Pluvicto. More than 85% of patients in the trial who had no prior treatment and 58.8% of those who received chemotherapy first had PSA levels fall by half, according to data \u200bpresented at the American Society of Clinical Oncology meeting in Chicago.<\/p>\n<\/div>\n<div>\n<p>TD Cowen analysts said the \u2060early \u2060data suggest clear efficacy, but \u2060cautioned that managing \u200bside effects, particularly high rates of dry mouth and severe anemia, will be crucial.<\/p>\n<\/div>\n<div>\n<p>Novartis Chief \u200bMedical Officer Shreeram Aradhye said \u2060larger trials will be needed to fully assess the severity and reversibility of those side effects, especially if the drug is used in earlier lines of treatment.<\/p>\n<\/div>\n<div>\n<p>The Swiss drugmaker is deepening its bet on radioligand therapies that deliver radiation directly to cancer cells, and is moving ahead with two late-stage \u2060studies of the experimental drug. Radioligand therapies now account for nearly 40% of Novartis&#8217; \u2060cancer R&amp;D investments, Aradhye said.<\/p>\n<\/div>\n<div>\n<p>The company already sells Pluvicto and Lutathera, which brought in a combined $2.8 billion last year.<\/p>\n<p>Read more <a href=\"https:\/\/officemovingamerica.com\/?p=169\">Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate<\/a><\/p>\n<\/div>\n<div>\n<p>Radiopharma is a fast-growing area of cancer treatment. Eli Lilly, Bristol Myers Squibb, Bayer and AstraZeneca have all acquired radio-drug developers in recent years.<\/p>\n<\/div>\n<div><\/div>\n<div>\n<p>The therapies link a radioactive isotope to a molecule designed to seek out cancer-cell targets. While Pluvicto uses lutetium-177, a beta-emitting isotope, the experimental drug uses actinium-225, an alpha emitter.<\/p>\n<\/div>\n<div>\n<p>&#8220;The difference is that much higher amounts of energy (are) delivered across a much smaller distance, and \u2060the potential for greater efficacy,&#8221; Aradhye said.<\/p>\n<\/div>\n<div>\n<div><\/div>\n<\/div>\n<div>\n<p>Some analysts have warned that the current actinium-225 supply is insufficient for growing clinical demand, though newer production efforts could ease constraints.<\/p>\n<\/div>\n<div>\n<p>Aradhye said Novartis is already planning around future isotope needs. In February, the company entered into a \u200blong-term supply agreement for actinium with U.S.-based medical isotope producer Niowave.<\/p>\n<p>Read more <a href=\"https:\/\/officemovingamerica.com\/?p=168\">New Jersey State Police Assert Control Outside Migrant Detention Center<\/a><\/p>\n<\/div>\n<div><\/div>\n<div>\n<p>(Reporting by \u200bBhanvi Satija in London; Editing by Bill Berkrot)<\/p>\n<\/div>\n<div>\n<p><b>Copyright 2026 Thomson Reuters<\/b>.<\/p>\n<\/div>\n<div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.<\/p>\n","protected":false},"author":1,"featured_media":172,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[66],"tags":[127,80,8,113,60],"class_list":["post-173","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-news","tag-cancer","tag-europe","tag-sign-in-to-manage-your-newsletters","tag-switzerland","tag-united-states"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Experimental Novartis Radiopharma Drug Shows Promise in Early Study - Office Moving America<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/officemovingamerica.com\/?p=173\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Experimental Novartis Radiopharma Drug Shows Promise in Early Study - Office Moving America\" \/>\n<meta property=\"og:description\" content=\"US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/officemovingamerica.com\/?p=173\" \/>\n<meta property=\"og:site_name\" content=\"Office Moving America\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-31T12:44:34+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#\\\/schema\\\/person\\\/953f33efe585ac76cdf8428d434d3061\"},\"headline\":\"Experimental Novartis Radiopharma Drug Shows Promise in Early Study\",\"datePublished\":\"2026-05-31T12:44:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173\"},\"wordCount\":443,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/officemovingamerica.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/802c405090779dcd3b15fd144c327bda.jpg\",\"keywords\":[\"cancer\",\"Europe\",\"Sign in to manage your newsletters \u00bb\",\"Switzerland\",\"United States\"],\"articleSection\":[\"Top News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173\",\"url\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173\",\"name\":\"Experimental Novartis Radiopharma Drug Shows Promise in Early Study - Office Moving America\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/officemovingamerica.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/802c405090779dcd3b15fd144c327bda.jpg\",\"datePublished\":\"2026-05-31T12:44:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#\\\/schema\\\/person\\\/953f33efe585ac76cdf8428d434d3061\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/officemovingamerica.com\\\/?p=173\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#primaryimage\",\"url\":\"https:\\\/\\\/officemovingamerica.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/802c405090779dcd3b15fd144c327bda.jpg\",\"contentUrl\":\"https:\\\/\\\/officemovingamerica.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/802c405090779dcd3b15fd144c327bda.jpg\",\"width\":800,\"height\":486,\"caption\":\"FILE PHOTO: The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS\\\/Arnd Wiegmann\\\/File Photo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=173#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/officemovingamerica.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Experimental Novartis Radiopharma Drug Shows Promise in Early Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#website\",\"url\":\"https:\\\/\\\/officemovingamerica.com\\\/\",\"name\":\"Office Moving America\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/officemovingamerica.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#\\\/schema\\\/person\\\/953f33efe585ac76cdf8428d434d3061\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/officemovingamerica.com\"],\"url\":\"https:\\\/\\\/officemovingamerica.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Experimental Novartis Radiopharma Drug Shows Promise in Early Study - Office Moving America","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/officemovingamerica.com\/?p=173","og_locale":"en_US","og_type":"article","og_title":"Experimental Novartis Radiopharma Drug Shows Promise in Early Study - Office Moving America","og_description":"US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.","og_url":"https:\/\/officemovingamerica.com\/?p=173","og_site_name":"Office Moving America","article_published_time":"2026-05-31T12:44:34+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/officemovingamerica.com\/?p=173#article","isPartOf":{"@id":"https:\/\/officemovingamerica.com\/?p=173"},"author":{"name":"admin","@id":"https:\/\/officemovingamerica.com\/#\/schema\/person\/953f33efe585ac76cdf8428d434d3061"},"headline":"Experimental Novartis Radiopharma Drug Shows Promise in Early Study","datePublished":"2026-05-31T12:44:34+00:00","mainEntityOfPage":{"@id":"https:\/\/officemovingamerica.com\/?p=173"},"wordCount":443,"commentCount":0,"image":{"@id":"https:\/\/officemovingamerica.com\/?p=173#primaryimage"},"thumbnailUrl":"https:\/\/officemovingamerica.com\/wp-content\/uploads\/2026\/05\/802c405090779dcd3b15fd144c327bda.jpg","keywords":["cancer","Europe","Sign in to manage your newsletters \u00bb","Switzerland","United States"],"articleSection":["Top News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/officemovingamerica.com\/?p=173#respond"]}]},{"@type":"WebPage","@id":"https:\/\/officemovingamerica.com\/?p=173","url":"https:\/\/officemovingamerica.com\/?p=173","name":"Experimental Novartis Radiopharma Drug Shows Promise in Early Study - Office Moving America","isPartOf":{"@id":"https:\/\/officemovingamerica.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/officemovingamerica.com\/?p=173#primaryimage"},"image":{"@id":"https:\/\/officemovingamerica.com\/?p=173#primaryimage"},"thumbnailUrl":"https:\/\/officemovingamerica.com\/wp-content\/uploads\/2026\/05\/802c405090779dcd3b15fd144c327bda.jpg","datePublished":"2026-05-31T12:44:34+00:00","author":{"@id":"https:\/\/officemovingamerica.com\/#\/schema\/person\/953f33efe585ac76cdf8428d434d3061"},"breadcrumb":{"@id":"https:\/\/officemovingamerica.com\/?p=173#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/officemovingamerica.com\/?p=173"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/officemovingamerica.com\/?p=173#primaryimage","url":"https:\/\/officemovingamerica.com\/wp-content\/uploads\/2026\/05\/802c405090779dcd3b15fd144c327bda.jpg","contentUrl":"https:\/\/officemovingamerica.com\/wp-content\/uploads\/2026\/05\/802c405090779dcd3b15fd144c327bda.jpg","width":800,"height":486,"caption":"FILE PHOTO: The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS\/Arnd Wiegmann\/File Photo"},{"@type":"BreadcrumbList","@id":"https:\/\/officemovingamerica.com\/?p=173#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/officemovingamerica.com\/"},{"@type":"ListItem","position":2,"name":"Experimental Novartis Radiopharma Drug Shows Promise in Early Study"}]},{"@type":"WebSite","@id":"https:\/\/officemovingamerica.com\/#website","url":"https:\/\/officemovingamerica.com\/","name":"Office Moving America","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/officemovingamerica.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/officemovingamerica.com\/#\/schema\/person\/953f33efe585ac76cdf8428d434d3061","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/officemovingamerica.com"],"url":"https:\/\/officemovingamerica.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/posts\/173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=173"}],"version-history":[{"count":0,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/posts\/173\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/media\/172"}],"wp:attachment":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}